Solifenacin

Urologic Clinics of North America

Volumn 33, Issue 4, 2006, Pages 483-490

  Kreder, Karl J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; DARIFENACIN; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; WARFARIN;

AREA UNDER THE CURVE; BLADDER DYSFUNCTION; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; URGE INCONTINENCE; XEROSTOMIA;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE;

EID: 33748983378     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2006.06.008     Document Type: Review

References (20)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 61 1 (2003) 37-49
2. Stewart W., Herzog R., and Wein A. Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodynam 20 (2001) 406-408
3. Versi E. Screening initiative confirms widespread prevalence of overactive bladder in American adults. Int Urogynecol J 12 (2001) S13
4. Smulders R.A., Krauwinkel W.J., Swart P.J., et al. Pharmakokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 44 9 (2004) 1023-1033
5. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Arch Pharmacol 366 2 (2002) 97-103
6. Krauwinkel W.J., Smulders R.A., Mulder H., et al. Effect of age on the pgarmacokinetics of solifenacin in men and women. Int J Pharmacol Ther 43 5 (2005) 227-238
7. Chapple C.R., Rechberger T., Al-Shukri S., et al., on behalf of the YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93 3 (2004) 303-310
8. ®. Available at: www.vesicare.com/pdf/vesicare_prescribing_info.pdf.
9. Andersson K.-E., and Wein A.J. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 56 4 (2004) 581-631
10. Yamaguchi O., Shishido K., Tamura K., et al. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 156 3 (1996) 1208-1213
11. Sigala S., Mirabella G., Peroni A., et al. Differential gene expresion of cholonergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology 60 4 (2002) 719-725
12. 2+-activated K+ channels in rat bladder smooth muscle. Int J Urol 9 12 (2002) 689-696
13. Ohtake A., Ukai M., Hatanaka T., et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 492 2-3 (2004) 243-250
14. 2+ mobilization study in monkey cells. Life Sci 74 7 (2004) 843-853
15. Michel M.C., Minematsu T., Hashimoto T., et al. In vitro studies on the potential of solifenacin for drug-drug interactions: plasma protein binding and MDR1 transport. [abstract]. Br J Clin Pharmacol 59 5 (2005) 647
16. Uchida T., Krauwinkel W.J., Mulder H., et al. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br J Clin Pharmacol 58 1 (2004) 4-7
17. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48 3 (2005) 464-470
18. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172 5 (2004) 1919-1924
19. Haab F., Cardozo L., Chapple C., et al., for the Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47 3 (2005) 376-384
20. Kelleher C.J., Cardozo L., Chapple C.R., et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 95 1 (2005) 81-85